Fulgent Genetics Inc (FLGT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Fulgent Genetics Inc stock (FLGT) is currently trading at $16.67. Fulgent Genetics Inc PS ratio (Price-to-Sales) is 1.47. Analyst consensus price target for FLGT is $24.33. WallStSmart rates FLGT as Sell.
- FLGT PE ratio analysis and historical PE chart
- FLGT PS ratio (Price-to-Sales) history and trend
- FLGT intrinsic value — DCF, Graham Number, EPV models
- FLGT stock price prediction 2025 2026 2027 2028 2029 2030
- FLGT fair value vs current price
- FLGT insider transactions and insider buying
- Is FLGT undervalued or overvalued?
- Fulgent Genetics Inc financial analysis — revenue, earnings, cash flow
- FLGT Piotroski F-Score and Altman Z-Score
- FLGT analyst price target and Smart Rating
Fulgent Genetics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Fulgent Genetics Inc (FLGT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Fulgent Genetics Inc (FLGT) Key Strengths (4)
Trading below book value, meaning the market prices it less than net assets
Good growth relative to its price
Paying $1.47 for every $1 of annual revenue
59.02% held by institutions, strong professional interest
Supporting Valuation Data
Fulgent Genetics Inc (FLGT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Earnings declining -98.60%, profits shrinking
Company is losing money with a negative profit margin
Modest revenue growth at 9.30%
Small-cap company with higher risk but more growth potential
Fulgent Genetics Inc (FLGT) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, PEG Ratio, Price/Sales. Valuation metrics including PEG Ratio (1.32), Price/Sales (1.47), Price/Book (0.42) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Growth concerns include Revenue Growth at 9.30%, EPS Growth at -98.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -5.51%, Operating Margin at -41.20%, Profit Margin at -18.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -5.51% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FLGT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FLGT's Price-to-Sales ratio of 1.47x trades at a deep discount to its historical average of 7.53x (11th percentile). The current valuation is 96% below its historical high of 38.61x set in Nov 2020, and 58% above its historical low of 0.93x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~1.9x as trailing revenue scaled faster than the stock price.
Compare FLGT with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Fulgent Genetics Inc (FLGT) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Fulgent Genetics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 323M with 9% growth year-over-year. The company is currently unprofitable, posting a -18.8% profit margin.
Key Findings
The company is unprofitable with a -18.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -83M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Fulgent Genetics Inc.
Bottom Line
Fulgent Genetics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Fulgent Genetics Inc(FLGT)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.